## Edgar Filing: Emergent BioSolutions Inc. - Form 4

•	oSolutions Inc.										
Form 4	<i>.</i>										
April 05, 201											
FORM	4		CECUE					NCEC		OMB AF	PROVAL
UNITED STATES SECURITIES AND EXCH Washington, D.C. 2054								OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 19					e Act of 1934,	Expires: January 31 2009 Estimated average burden hours per response 0.4					
obligatior may conti <i>See</i> Instru 1(b).	inue. Section 17		Public Ut of the In	•		•	· ·		1935 or Section 0	1	
(Print or Type R	Responses)										
1. Name and A Abdun-Nabi	ddress of Reporting Daniel	g Person <u>*</u>	2. Issuer Symbol Emerger	<sup>.</sup> Name <b>a</b> nt BioS				-	5. Relationship of Issuer	Reporting Pers	
(Last) 400 PROFE 400	(First)	(Middle) SUITE	3. Date of (Month/D 03/11/20	ay/Year)		nsaction			X Director X Officer (give below)	10%	Owner er (specify
	(Street)		4. If Ame Filed(Mon			original	l		6. Individual or Jo Applicable Line) _X_ Form filed by C		
GAITHERS	BURG, MD 20	879							Form filed by M Person		
(City)	(State)	(Zip)	Tabl	e I - Non	1-De	rivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	<ul> <li>Execution any</li> </ul>		3. Transac Code (Instr. 8 Code	ction( ( 3)	4. Securit (A) or Di (Instr. 3, Amount	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
Common Stock (1)	03/11/2016			F	(	6,493	D	\$ 34.22	197,068	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title o Derivati Security (Instr. 3)	ve Conversion or Exercise	3. Transaction Date (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of ) Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year) ive es ed ed		Amou Unde Secur	ele and unt of rlying rities (1, 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Emergent BioSolutions Inc. - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Abdun-Nabi Daniel 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879	Х		President & CEO				
Signatures							
s/ Eric Burt.							

attorney-in-fact	04/05/2016			
<u>**</u> Signature of Reporting Person	Date			

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as (1) amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.